209 studies found for:    Open Studies | "Influenza, Human"
Show Display Options
Rank Status Study
21 Recruiting Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Conditions: Pregnancy;   Influenza
Intervention: Biological: Quadrivalent Influenza Vaccine (QIV)
22 Recruiting Banlangen Granules Anti-seasonal Influenza Study
Condition: Influenza
Interventions: Drug: placebo of oseltamivir phosphate;   Drug: oseltamivir phosphate;   Drug: Banlangen (Radix Isatidis) granules;   Drug: placebo of Banlangen(Radix Isatidis) granules
23 Not yet recruiting Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
Condition: Influenza
Intervention: Biological: Fluarix Tetra
24 Unknown  Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
Condition: Pandemic Influenza
Intervention: Biological: Pandemic Influenza Vaccine (H5N1)
25 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine (no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
26 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine(no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
27 Not yet recruiting Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly
Condition: Influenza
Intervention: Biological: Butantan Fragmented Inactivated Trivalent Influenza Vaccine
28 Unknown  Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
Condition: Influenza
Interventions: Biological: TCN-032;   Biological: Placebo (saline)
29 Unknown  Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada
Conditions: Influenza;   Pneumonia
30 Unknown  Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza
Condition: Influenza
Interventions: Drug: Interferon alfacon-1;   Drug: Placebo
31 Recruiting Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV
Condition: Influenza
Intervention: Biological: M-001
32 Recruiting Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units
Condition: Patient With Influenza Like Illness
Intervention: Biological: A nasal swab
33 Unknown  e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus
Condition: Influenza Caused by Unspecified Influenza Virus
Intervention: Device: Electrosensing antibody probing system (e- Ab sensor)
34 Recruiting H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...
Condition: Influenza
Interventions: Biological: A/Shanghai/02/2013 (H7N9) MIV;   Biological: VRC-FLUDNA071-00-VP
35 Not yet recruiting A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).
Condition: Live Attenuated Influenza Vaccine
Intervention: Drug: Fluenz
36 Recruiting Safety Study of FluMist With and Without Ampligen
Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U 50 ug;   Drug: FluMist + Poly I:Poly C12U 200 ug;   Drug: FluMist + Poly I:Poly C12U 500 ug;   Drug: FluMist + Poly I:Poly C12U 1250 ug;   Drug: FluMist + Placebo
37 Recruiting A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
Condition: Influenza Vaccine Effectiveness
38 Not yet recruiting A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
Condition: Avian Influenza
Interventions: Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013;   Drug: MF59;   Biological: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
39 Not yet recruiting Mail Outreach To Increase Vaccination Acceptance Through Engagement
Conditions: Influenza, Human;   Influenza;   Human Flu
Interventions: Behavioral: Core letter signed by Surgeon General;   Behavioral: Core letter signed by the Director of the National Vaccine Program;   Behavioral: Core letter signed by Surgeon General + implementation prompt;   Behavioral: Core letter signed by SG + enhanced implementation prompt
40 Recruiting Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 A/Anhui/13 ca influenza virus vaccine;   Biological: Inactivated subvirion H7N9 vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years